Medical laser device maker Lumenis (Nasdaq: LUME) announced today that it had received FDA clearance to market its BClear Targeted PhotoClearing system for the treatment of atopic eczema and seborrheic dermatitis.
In December 2001, the FDA approved the BClear system for the treatment of psoriasis and vitiligo.
Lumenis says Bclear is a unique light-based therapy that combines the proven benefits of phototherapy with the latest advances in fiber-optic technology. The computerized BClear system delivers targeted light through a fiber-optic cable, in significantly higher doses than those used in traditional UVB light therapy. Lumenis says the higher doses of light allow patients to experience successful results in fewer treatment sessions, with generally very limited side-effects.
Lumenis president and CEO Yacha Sutton said, "Treating eczema and dermatitis with the BClear system can bring relief to millions of patients, especially children and young adults who suffer from these skin conditions. We are very excited about offering this drug free alternative to traditional treatment options including topical and oral medications such as corticosteroids, antihistamines and antibiotics."
Lumenis Aesthetic Business unit executive vice president Alon Maor said, "Medicare reimbursement rates were recently raised to more than $50 per treatment. We expect that the combination of a safe and effective, localized UVB treatment -- and improved reimbursement rates -- to substantially increase the number of patient visits to dermatologists' offices for these procedures."
Lumenis shares were up 7.3% at $5.13 in morning trade on the Nasdaq on Wednesday.
Published by Globes [online] - www.globes.co.il - on 22 May, 2002